[1] |
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2017[J]. CA cancer J Clin, 2017, 57(1):43-66.
|
[2] |
Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration[J]. Int J Cancer, 2015, 137(9): 2060-2071.
|
[3] |
Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6):2099-2108.
|
[4] |
Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer[J]. Curr Epidemiol Rep, 2019, 6(2):104-111.
|
[5] |
Liu CY, Chen KF, Chen PJ. Treatment of liver cancer[J]. Cold Spring Harb Perspect Med, 2015, 5(9):021535.
|
[6] |
Imamura H, Seyama Y, Kokudo N, et al. One thousand fifty-six hepatectomies without mortality in 8 years[J]. Arch Surg, 2003, 138(11):1198-1206.
|
[7] |
中国研究型医院学会肝胆胰外科专业委员会. 精准肝切除术专家共识[J]. 中华消化外科杂志, 2017, 16(9):883-893.
|
[8] |
曹君,陈亚进. 浅谈腹腔镜肝切除之入路[J]. 中华外科杂志, 2019, 57(7):503-507.
|
[9] |
Li W, Zhou X, Huang Z, et al. Laparoscopic surgery minimizes the release of circulating tumor cells compared to open surgery for hepatocellular carcinoma[J]. Surg Endosc, 2015, 29(11):3146-3153.
|
[10] |
Wada H, Eguchi H, Nagano H, et al. Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis[J]. Surg Today, 2018, 48(1):73-79.
|
[11] |
荚卫东,陈浩,葛勇胜, 等. 三维可视化技术在巨块型肝细胞癌精准肝切除中的应用价值[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(1):35-39.
|
[12] |
陈耿,孔一帆,别平. 剩余肝体积不足的肝癌手术切除策略[J/OL]. 中华肝脏外科手术学电子杂志, 2020, 9(2):104-107.
|
[13] |
李健,文张,徐邦浩, 等. 联合门静脉切除重建的ALPPS治疗肝内胆管细胞癌[J/OL].中华肝脏外科手术学电子杂志, 2020, 9(1): 62-66.
|
[14] |
周俭,王征,孙健, 等. 联合肝脏离断和门静脉结扎的二步肝切除术[J]. 中华消化外科杂志, 2013, 12(7):485-489.
|
[15] |
李旻骏,滕煜宪,黎晴, 等. 血清前白蛋白与肝细胞癌患者肝切除术预后的相关性研究[J]. 中华肝胆外科杂志, 2020, 26(1):27-31.
|
[16] |
Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer[J]. Cells, 2020, 9(3):561.
|
[17] |
Afify SM, Sanchez Calle A, Hassan G, et al. A novel model of liver cancer stem cells developed from induced pluripotent stem cells[J]. Br J Cancer, 2020, 122(9):1378-1390.
|
[18] |
董家鸿,冷建军,杨占宇. 肝脏移植手术图解[M]. 上海: 上海科技教育出版社, 2013.
|
[19] |
Pratschke S, Rauch A, Albertsmeier M, et al. Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce intraoperative blood loss and improve postoperative transaminases and renal function: a meta-analysis[J]. World J Surg, 2016, 40(12):2988-2998.
|
[20] |
杨占宇,唐腾骞. 优化肝移植术后免疫抑制治疗方案[J]. 中华消化外科杂志, 2013, 12(9):652-654.
|
[21] |
中华医学会器官移植学分会. 中国肝移植受者选择与术前评估技术规范(2019版)[J/CD]. 中华移植杂志(电子版), 2019, 13(3):161-166.
|
[22] |
Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria[J]. Hepatology, 2015, 61(1):1968-1977.
|
[23] |
Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery, 2017, 162(6):1250-1258.
|
[24] |
Varkaris A, Lewis DW, Nugent FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma[J]. Am J Gastroenterol, 2017, 112(12):1895-1896.
|